Figure 1. Optimisation of bortezomib concentration by comparison
with 10 µM MG132. (A) Schematic of the experimental workflow. HFFF-TERT
cells were infected with Merlin strain HCMV (MOI 5) or mock infected and
simultaneously treated with 10 µM MG132, 500 nM, 1 µM or 2 µM
bortezomib. Samples were harvested at 12 hpi to maximise the ability to
study very early infection as we previously described (Nightingale et
al., 2018). Whole cell lysates were digested into peptides, which were
labelled with TMT reagents followed by MS3 mass spectrometry. (B)
Comparison of 10µM MG132 with 500 nM, 1 µM or 2 µM bortezomib (bort).